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histochemical	 expression	 of	 estrogens	 and	 progesterone	 receptors	 (ER	 and	 PR)	
predicts	the	treatment	response.











curacy	 (AUC	=	.637).	 Negative	 PR	 significantly	 predicted	 poor	 response	 (P	=	.01),	
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1  | INTRODUC TION
Endometrial	 hyperplasia	 (EH)	 is	 an	 irregular	 proliferation	 of	 endo‐
metrial	 glands	which	 often	 precedes	 endometrial	 cancer	 of	 endo‐
metrioid	type.1‐3	Several	studies	have	shown	that	EH	includes	both	
hyperproliferative	 reactions	 to	 an	 unbalanced	 action	 of	 estrogens	
and	true	precancerous	lesions.1,2,4
The	revised	2014	WHO	classification	of	EH	differentiates	be‐



















(ER)	 and	 progesterone	 receptor	 (PR),	 whose	 expression	 is	 eas‐
ily	 assessable	 by	 immunohistochemistry.12‐24	 Estrogens	 are	 in‐
deed	involved	in	the	development	of	EH	and	EC,	and	progestins	
mediate	 their	 action	 through	PR.2,12	 In	 spite	of	 this,	 results	 are	





2  | MATERIAL AND METHODS
This	 study	 was	 performed	 following	 the	 SEDATE	 guidelines.25 
The	 study	 protocol	 was	 designed	 a	 priori,	 defining	methods	 for	
collecting,	extracting	and	analyzing	data.	All	 review	stages	were	
conducted	 independently	by	 two	 reviewers	 (A.R.,	A.T.).	The	 two	




Two	 reviewers	 (A.R.,	 A.T.)	 independently	 conducted	 several	






medroxyprogesterone;	 MPA;	 mirena;	 LNG;	 levonorgestrel;	 pro‐
gestogen;	 progestin;	 response;	 resistance;	 persistence;	 outcome;	





•	 study	 population	 constituted	 of	 women	 diagnosed	 with	 EH	 or	
EEC	and	conservatively	treated	with	progestins;
•	 assessment	of	 the	 expression	of	 the	marker	 (ER	or	PR)	 on	pre‐
treatment	endometrial	specimens	by	immunohistochemistry;
•	 assessment	 of	 the	 association	 between	 the	 expression	 of	 the	
marker	and	the	response	to	therapy.
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Reference	test	(low	risk	if	good	response	was	defined	as	absence	
of	any	lesions;	unclear	risk	if	histologic	criteria	defining	good	re‐
sponse	were	 incomplete;	 high	 risk	 if	 authors	 considered	even	 a	
partial	regression	as	good	response);	(4)	Flow	and	timing	(low	risk	
if	 the	follow	up	was	at	 least	3	months;	unclear	risk	 if	 the	follow	
up	was	1‐3	months;	high	risk	if	follow	up	was	<1	months	or	if	hor‐
mone	 receptors	were	assessed	on	biopsies	withdrawn	after	 the	




omous	 qualitative	 variables	 were	 assessed:	 immunohistochemical	
expression	on	pretreatment	biopsy	(“positive”	vs	“negative”)	and	re‐
sponse	to	conservative	therapy	(“good”	vs	“poor”).
The	expression	of	 the	marker	was	considered	 “negative”	 if	 the	
























We	 calculated	 the	 predictive	 accuracy	 of	 the	 immunohisto‐
chemical	assessment	of	ER	and	PR	to	define	its	clinical	usefulness	in	
predicting	the	response	to	conservative	treatment	of	EH	and	EEC.	
Sensitivity,	 specificity,	 positive	 likelihood	 ratio	 (LR+),	 negative	 like‐










We	 defined	 a	 priori	 that	 only	 a	 high	 predictive	 accuracy	
(AUC	>.9)	 would	 have	 indicated	 an	 actual	 clinical	 usefulness,	
since	 conservatively	 treated	 patients	 with	 atypical	 EH	 and	 EEC	
are	 already	 closely	 followed	 with	 endometrial	 biopsies	 every	
3‐6	months	due	 to	 the	 risk	of	progression	 to	 invasive	disease.	 If	
SROC	calculation	was	not	available	due	to	an	insufficient	number	
of	 studies,	we	 adopted	 LR+	 and	 LR−	 as	 surrogates,	which	would	
have	been	>10	and	<.1,	respectively,	to	indicate	an	actual	clinical	
usefulness.25












ranged	 between	 19	 and	 77	years;	 body	 mass	 index	 (BMI)	 ranged	
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For	the	“Index	test”	domain,	with	regard	to	ER,	6	studies	were	










The	 studies	 at	 high	 risk	 of	 bias	 were	 excluded	 from	 the	
meta‐analysis.




CI	 .74‐6.52;	 P	=	.16),	 with	moderate	 heterogeneity	 among	 studies	
(I2 =	52%)	(Figure	1a).





















.13‐1.41;	 P	=	.55)	 and	 without	 heterogeneity	 (I2 =	0%)	 (Figure	1b).	
Sensitivity	 and	 specificity	were	 .14	 (95%	CI	 .00‐.58)	 and	 .79	 (95%	
F I G U R E  2  Plots	reporting	prognostic	accuracy	metrics	for	estrogen	receptor	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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CI	 .61‐.91),	 respectively,	with	LR+	 and	LR−	of	 .69	 (95%	CI	 .19‐2.50)	
and	1.28	(95%	CI	.37‐4.45),	respectively,	and	a	DOR	of	.53	(95%	CI	
.05‐5.94).	Heterogeneity	among	studies	was	absent	for	DOR	and	LR+ 













.71‐6.24;	 P	=	.18)	 and	 without	 heterogeneity	 (I2 =	0%)	 (Figure	1e).	





















and	1.00	 (95%	CI	 .89‐1.12),	 respectively,	and	a	DOR	of	 .83	 (95%	
CI	 .19‐5.89).	 SROC	 analysis	 showed	 no	 predictive	 accuracy	 and	
F I G U R E  3  Plots	reporting	prognostic	accuracy	metrics	for	progesterone	receptor	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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no	clinical	usefulness,	with	an	AUC	of	.304.	Heterogeneity	among	
studies	 was	 low	 for	 sensitivity	 (I2 =	41%),	 high	 for	 specificity	
(I2 =	88.2%),	and	absent	for	LR+,	LR−	and	DOR	(I2 =	0%)	(Supporting	
Information	Figure	S3).
In	 the	 subgroup	of	 patients	with	 atypical	 EH	and/or	EEC,	PR	
was	 not	 significantly	 predictive	 of	 response,	with	 an	 RR	 of	 1.79	
(95%	 CI	 .70‐4.57;	 P	=	.22)	 and	 without	 heterogeneity	 (I2 =	0%)	
(Figure	1f).	 Sensitivity	 and	 specificity	 were	 .22	 (95%	 CI	 .07‐.44)	
and	 .89	 (95%	 CI	 .82‐.94),	 respectively,	 with	 LR+	 and	 LR−	 of	 2.12	
(95%	 CI	 .90‐5.01)	 and	 .97	 (95%	 CI	 .75‐1.26),	 respectively,	 and	 a	
DOR	 of	 2.18	 (95%	 CI	 .85‐8.61).	 SROC	 analysis	 showed	 moder‐
ate	predictive	accuracy	and	no	actual	clinical	usefulness,	with	an	
AUC	of	.828.	Heterogeneity	among	studies	was	moderate	for	sen‐




In	 the	 assessment	of	 the	 risk	of	bias	 across	 studies	 for	ER,	 al‐
though	the	funnel	plot	showed	an	evident	asymmetry,	 the	studies	





Our	 study	 showed	 that	 ER	 and	 PR	 expression	 in	 EH	 and	 EEC	 are	
predictive	of	response	to	LNG‐IUD,	whereas	they	do	not	have	sig‐
nificant	predictive	value	if	oral	progestins	are	administered.
ER	 and	 PR	 are	 nuclear	 receptors	 which	 play	 a	 crucial	 role	 in	
endometrial	 carcinogenesis.	 ER	mediates	 the	 action	 of	 estrogens,	




(disordered	 proliferative	 endometrium),	 which	 leads	 to	 EH.36	 The	
increased	 and	 continued	 stimulation	 to	 proliferate	 predisposes	 to	
the	development	of	genetic	mutations	with	the	emergence	of	a	neo‐
plastic	 clone	 (atypical	 EH/endometrioid	 intraepithelial	 neoplasia),	
initiating	 the	 carcinogenesis,4,36	Most	 atypical	 EH	 and	well	 differ‐
entiated	EEC	of	endometrioid	type,	(“type	1	endometrial	cancer”	in	
F I G U R E  4  Forest	plots	reporting	prognostic	accuracy	metrics	for	estrogen	receptor	in	the	subgroup	treated	with	oral	progestins	(a)	and	
LNG‐IUD	(b)	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]









Progestins	 have	 been	 widely	 used	 for	 the	 conservative	 treat‐
ment	of	EH	and	EEC,	since	they	antagonize	the	growth‐promoting	
action	of	estrogens,	stimulating	apoptosis	in	endometrial	cells.35,38
Among	 the	 available	 progestin‐based	 treatments,	 LNG‐IUD	
showed	better	efficacy	than	oral	progestin,	as	highlighted	by	several	

















significantly	 predictive	 of	 response	 (RR),	with	moderate	 accuracy.	







F I G U R E  5  Forest	plots	reporting	prognostic	accuracy	metrics	for	progesterone	receptor	in	the	subgroup	treated	with	oral	progestins	(a)	
and	LNG‐IUD	(b)	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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it	was	not	 significant	 in	 the	case	of	oral	 administration	of	proges‐
tin.	These	results	might	be	explained	by	the	stronger	local	effect	of	
LNG‐IUD:	if	intrauterine	administration	activates	a	higher	percent‐






significant	 results	may	be	explained	by	 the	 fact	 that	no	 studies	 in	
this	 subgroup	exclusively	 considered	LNG‐IUD.	Therefore,	 further	
studies	are	necessary	in	this	regard.
However,	even	in	the	LNG‐IUD	subgroup,	the	predictive	useful‐
ness	appeared	 insufficient,	with	a	 low	sensitivity	 for	both	ER	and	




























Although	 our	 study	 substantially	 confirms	 the	 guidance	 of	
ESMO‐ESGO‐ESTRO,	 it	may	provide	a	higher	 level	of	evidence	 to	
support	this	position,	which	was	based	on	only	one	small	study.
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F I G U R E  6  Funnel	plots	for	the	assessment	of	risk	of	bias	across	
studies	about	estrogen	receptor	(a)	and	progesterone	receptor	(b)	
[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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